Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutrope-nia in Patients with Epithelial Ovarian Cancer in China:Based on Real-Word Data
OBJECTIVE To evaluate the cost-effectiveness of PEG-rhG-CSF versus rhG-CSF in patients with epithelial ovarian cancer in central China for preventing chemotherapy-induced neutropenia.METHODS Two Markov models form healthcare system perspective were developed to evaluate the economics of PEG-rhG-CSF versus rhG-CSF using cost-utility analysis.Cost and probability input data were primarily obtained from a retrospective real-world study conducted in four tertiary hospitals from January 2019 to De-cember 2020.One-way sensitivity analysis,probability sensitivity analysis and scenario analysis were used to verify the robustness of the results.RESULTS The basic analysis showed that,compared with rhG-CSF,PEG-rhG-CSF resulted in higher QALYs and lower cost,gained 0.27 QALYs more while spending 2279.63 yuan less,and the incremental cost-effectiveness ratios were ¥-8393.9/QA-LY.Sensitivity analysis and scenario analysis revealed robust results.CONCLUSION PEG-rhG-CSF is economically advantageous in Chinese patients with epithelial ovarian cancer for preventing chemotherapy-induced neutropenia.
万方数据
维普
